US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
FR2646438B1
(fr)
|
1989-03-20 |
2007-11-02 |
Pasteur Institut |
Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
|
ATE174058T1
(de)
*
|
1989-11-06 |
1998-12-15 |
Cell Genesys Inc |
Herstellung von proteinen mittels homologer rekombination
|
US5272071A
(en)
*
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
ATE156189T1
(de)
*
|
1989-12-22 |
1997-08-15 |
Applied Research Systems |
Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination
|
GB9028062D0
(en)
*
|
1990-12-24 |
1991-02-13 |
Agricultural & Food Res |
Production of transgenic animals
|
WO1992019255A1
(fr)
*
|
1991-05-06 |
1992-11-12 |
Cell Genesys, Inc. |
Manipulation et expression de genes a l'aide d'elements de genome
|
ES2214474T3
(es)
*
|
1991-05-31 |
2004-09-16 |
Genentech, Inc. |
Aumento de la expresion mediante orientacion genica en secuencias endogenas de tipo retrovirus.
|
AU2515992A
(en)
*
|
1991-08-20 |
1993-03-16 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
US6063630A
(en)
*
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US5641670A
(en)
*
|
1991-11-05 |
1997-06-24 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
NZ245015A
(en)
*
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US20020108136A1
(en)
*
|
1997-03-21 |
2002-08-08 |
Sri |
Transgenic animals produced by homologous sequence targeting
|
AU4401993A
(en)
*
|
1992-06-04 |
1993-12-30 |
Exemplar Corporation |
Insertion of heterologous dna outside of known chromosomal genes
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US5733753A
(en)
*
|
1992-12-22 |
1998-03-31 |
Novo Nordisk A/S |
Amplification of genomic DNA by site specific integration of a selectable marker construct
|
CA2161088A1
(fr)
|
1993-04-21 |
1994-10-27 |
Austin Gerard Smith |
Expression des genes heterologues selon un profil d'expression cible
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US5759775A
(en)
|
1994-10-27 |
1998-06-02 |
Genetech, Inc. |
Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
|
US6610296B2
(en)
|
1995-10-26 |
2003-08-26 |
Genentech, Inc. |
Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
|
ATE449849T1
(de)
|
1996-01-08 |
2009-12-15 |
Genentech Inc |
Ob rezeptor-variante und liganden
|
US7084252B1
(en)
|
1996-01-16 |
2006-08-01 |
The Rockefeller University |
DB, the receptor for leptin
|
US7148004B1
(en)
|
1997-01-16 |
2006-12-12 |
The Rockefeller University |
Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
|
US7063958B1
(en)
|
1996-01-16 |
2006-06-20 |
The Rockefeller University |
Nucleic acids db, the receptor for leptin
|
US7619079B2
(en)
|
1996-02-14 |
2009-11-17 |
The Rockefeller University |
Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
|
US5792210A
(en)
*
|
1996-06-10 |
1998-08-11 |
Environmental Behavior Modification Inc. |
Electrical tongue stimulator and method for addiction treatment
|
JP2000517185A
(ja)
|
1996-08-29 |
2000-12-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
新規なメタロプロテアーゼファミリーkuz
|
US6566089B1
(en)
*
|
1996-09-04 |
2003-05-20 |
Tularik Inc. |
Cell-based drug screens for regulators of gene expression
|
AU4424597A
(en)
*
|
1996-09-13 |
1998-04-02 |
Novo Nordisk Biotech, Inc. |
Cells having dna insertion mutations which produce altered amounts of a polypeptide
|
JPH10117771A
(ja)
*
|
1996-10-23 |
1998-05-12 |
Natl Food Res Inst |
冷凍生地耐性実用パン酵母
|
US5925544A
(en)
*
|
1996-11-18 |
1999-07-20 |
Novo Nordisk A/S |
Method of homologous recombination followed by in vivo selection of DNA amplification
|
US6326204B1
(en)
|
1997-01-17 |
2001-12-04 |
Maxygen, Inc. |
Evolution of whole cells and organisms by recursive sequence recombination
|
DE69835360T2
(de)
|
1997-01-17 |
2007-08-16 |
Maxygen, Inc., Redwood City |
EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION
|
US7148054B2
(en)
*
|
1997-01-17 |
2006-12-12 |
Maxygen, Inc. |
Evolution of whole cells and organisms by recursive sequence recombination
|
US6777196B2
(en)
|
1997-02-18 |
2004-08-17 |
Genentech, Inc. |
Neurturin receptor
|
US6372453B1
(en)
|
1997-02-18 |
2002-04-16 |
Genetech, Inc. |
Neurturin receptor
|
US6025157A
(en)
*
|
1997-02-18 |
2000-02-15 |
Genentech, Inc. |
Neurturin receptor
|
PT981637E
(pt)
|
1997-03-14 |
2005-09-30 |
Biogen Idec Inc |
Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo
|
US5948653A
(en)
*
|
1997-03-21 |
1999-09-07 |
Pati; Sushma |
Sequence alterations using homologous recombination
|
US6172211B1
(en)
|
1997-07-11 |
2001-01-09 |
Boehringer Ingelheim International Gmbh |
Nucleic acid encoding tag7 polypeptide
|
DK0986644T3
(da)
*
|
1997-07-23 |
2007-01-29 |
Roche Diagnostics Gmbh |
Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
|
US6391633B1
(en)
|
1997-07-23 |
2002-05-21 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
EP1000154B1
(fr)
*
|
1997-07-23 |
2007-02-21 |
Roche Diagnostics GmbH |
Identification de lignees cellulaires humaines pour la production de proteines humaines par activation genique endogene
|
PT1000154E
(pt)
|
1997-07-23 |
2007-03-30 |
Roche Diagnostics Gmbh |
Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
|
US6548296B1
(en)
|
1997-07-23 |
2003-04-15 |
Roche Diagnostics Gmbh |
Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
|
CA2304642C
(fr)
|
1997-09-26 |
2014-11-18 |
Athersys, Inc. |
Expression de genes endogenes par recombinaison non homologue d'une construction vectorielle a l'aide d'adn cellulaire
|
US7316923B1
(en)
|
1997-09-26 |
2008-01-08 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6897066B1
(en)
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
ZA989497B
(en)
†
|
1997-10-20 |
2000-04-19 |
Roche Diagnostics Gmbh |
Positive-negative selection in homologous recombination.
|
KR100760221B1
(ko)
|
1997-11-28 |
2007-10-30 |
세로노 제네틱스 인스티튜트 에스.에이. |
클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
|
AU757930B2
(en)
|
1997-12-01 |
2003-03-13 |
Roche Diagnostics Gmbh |
Optimization of cells for endogenous gene activation
|
JPH11243944A
(ja)
*
|
1998-03-04 |
1999-09-14 |
Natl Food Res Inst |
製パン用乾燥耐性実用パン酵母
|
US6294655B1
(en)
|
1998-04-03 |
2001-09-25 |
Hyseq, Inc. |
Anti-interleukin-1 receptor antagonist antibodies and uses thereof
|
US6337072B1
(en)
|
1998-04-03 |
2002-01-08 |
Hyseq, Inc. |
Interleukin-1 receptor antagonist and recombinant production thereof
|
US6541623B1
(en)
|
1998-04-03 |
2003-04-01 |
Hyseq, Inc. |
Interleukin—1 receptor antagonist and uses thereof
|
US6426191B1
(en)
|
1998-04-03 |
2002-07-30 |
Hyseq, Inc. |
Assays involving an IL-1 receptor antagonist
|
EP1098986B1
(fr)
|
1998-07-21 |
2011-12-28 |
Millipore Corporation |
Polynucleotide comportant un element d'ouverture de la chromatine ubiquiste (ucoe)
|
JP4486256B2
(ja)
*
|
1998-10-22 |
2010-06-23 |
ザ・ジェネラル・ホスピタル・コーポレイション |
副甲状腺ホルモン(PTH)および副甲状腺ホルモン関連ペプチド(PTHrP)の生物活性ペプチドおよびペプチド誘導体
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
TW570977B
(en)
*
|
1998-12-07 |
2004-01-11 |
Li-Wei Hsu |
An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
ES2321568T3
(es)
|
1999-05-18 |
2009-06-08 |
Dyax Corp. |
Bibliotecas de fragmentos fab y procedimientos para su uso.
|
US6495360B1
(en)
*
|
1999-05-28 |
2002-12-17 |
Photogen, Inc. |
Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
|
US20050129669A1
(en)
*
|
1999-06-21 |
2005-06-16 |
Transkaryotic Therapies, Inc., A Massachusetts Corporation |
DNA construct for effecting homologous recombination and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
ATE412670T1
(de)
|
1999-09-29 |
2008-11-15 |
Gen Hospital Corp |
Parathyroid hormon (pth) polypeptidderivate
|
AU7734800A
(en)
*
|
1999-09-29 |
2001-04-30 |
General Hospital Corporation, The |
Polypeptide derivatives of parathyroid hormone (pth)
|
AU1647501A
(en)
|
1999-12-10 |
2001-06-18 |
Cytos Biotechnology Ag |
Replicon based activation of endogenous genes
|
AU2001234443A1
(en)
*
|
2000-01-13 |
2001-07-24 |
Novozymes Biotech, Inc. |
Methods for producing a polypeptide using a crippled translational initiator sequence
|
AU2001243345A1
(en)
|
2000-02-29 |
2001-09-12 |
Millennium Pharmaceuticals, Inc. |
1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
|
EP1714661A3
(fr)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Procedes pour diagnostiquer et traiter des troubles hemostatiques par modulation de l'activité de la p-selectine
|
US6686188B2
(en)
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
GB0018876D0
(en)
*
|
2000-08-01 |
2000-09-20 |
Applied Research Systems |
Method of producing polypeptides
|
WO2002012437A2
(fr)
*
|
2000-08-03 |
2002-02-14 |
Schooten Wim Van |
Production d'anticorps humanises dans des animaux transgeniques
|
JP2003000268A
(ja)
|
2000-08-25 |
2003-01-07 |
Pfizer Prod Inc |
血管新生にかかわる疾患を診断および治療するための方法および組成物
|
ES2522890T3
(es)
|
2000-12-06 |
2014-11-19 |
Anthrogenesis Corporation |
Método para recolectar células troncales placentarias
|
US7311905B2
(en)
|
2002-02-13 |
2007-12-25 |
Anthrogenesis Corporation |
Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
|
US20030032179A1
(en)
|
2000-12-06 |
2003-02-13 |
Hariri Robert J. |
Post-partum mammalian placenta, its use and placental stem cells therefrom
|
ATE505204T1
(de)
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
MXPA03005406A
(es)
*
|
2000-12-20 |
2003-09-25 |
Hoffmann La Roche |
Conjugados de eritropoyetina.
|
PA8536201A1
(es)
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
|
KR101132545B1
(ko)
|
2001-02-14 |
2012-04-02 |
안트로제네시스 코포레이션 |
산후 포유류의 태반, 이의 용도 및 태반 줄기세포
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
EP2184359B1
(fr)
|
2001-06-06 |
2016-03-02 |
Bioriginal Food & Science Corp. |
Promoteurs spécifiques à la graine lin (Linum usitatissimum L.)
|
EP1925671A1
(fr)
|
2001-06-06 |
2008-05-28 |
Bioriginal Food & Science Corp. |
Promoteurs spécifiques à la graine lin (Linum usitatissimum L.)
|
US7572765B2
(en)
*
|
2001-07-23 |
2009-08-11 |
The General Hospital Corporation |
Conformationally constrained parathyroid hormone (PTH) analogs
|
JP2005511500A
(ja)
|
2001-08-31 |
2005-04-28 |
ザ ロックフェラー ユニバーシティー |
脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP1455815A4
(fr)
|
2001-12-19 |
2006-11-02 |
Millennium Pharm Inc |
Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
|
WO2003054172A2
(fr)
*
|
2002-01-17 |
2003-07-03 |
Lonza Biologics Plc. |
Cellules humaines auxotrophes pour la glutamine capables de produire des proteines et de se developper dans un milieu exempt de glutamine
|
NZ579705A
(en)
|
2002-02-13 |
2011-07-29 |
Anthrogenesis Corp |
Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
WO2003094841A2
(fr)
*
|
2002-05-06 |
2003-11-20 |
Functional Genetics, Inc. |
Genes de mammifere impliques dans une resistance a la rapamycine et une genese tumorale : genes d'annexine xiii
|
AU2003239589A1
(en)
|
2002-05-24 |
2003-12-12 |
Schering-Plough Ltd. |
Eta-1 gene and methods for use
|
AU2003265525A1
(en)
*
|
2002-08-15 |
2004-03-19 |
Functional Genetics, Inc. |
Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes
|
AU2003268135A1
(en)
*
|
2002-08-15 |
2004-03-19 |
Functional Genetics, Inc. |
Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
AU2003293013A1
(en)
|
2002-11-21 |
2004-06-18 |
University Of Massachusets |
Diagnosing and treating hematopoietic cancers
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
EP2112229A3
(fr)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Procédés d'identification du risque du cancer du sein et traitements associés
|
KR101042448B1
(ko)
|
2002-11-26 |
2011-06-16 |
안트로제네시스 코포레이션 |
세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
|
US20050048041A1
(en)
*
|
2003-01-13 |
2005-03-03 |
Rao Mahendra S. |
Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
|
CA2513226A1
(fr)
*
|
2003-01-13 |
2004-07-29 |
Mahendra S. Rao |
Molecule candidate a expression persistante dans des cellules souches et progenitrices destinee a l'apport de produits therapeutiques
|
ES2565327T3
(es)
|
2003-01-14 |
2016-04-04 |
Dana Farber Cancer Institute |
Sensibilizador de terapia del cáncer
|
US8021833B2
(en)
|
2003-02-12 |
2011-09-20 |
Functional Genetics, Inc. |
Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
|
AU2003220380A1
(en)
*
|
2003-03-19 |
2004-11-19 |
Bristol-Myers Squibb Company |
CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
|
JP4871128B2
(ja)
|
2003-07-17 |
2012-02-08 |
ザ ジェネラル ホスピタル コーポレイション |
高次構造的に制約された副甲状腺ホルモン(pth)アナログ
|
US7287952B2
(en)
*
|
2003-07-23 |
2007-10-30 |
Lockheed Martin Corporation |
Feeder load automation system and method of use
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
CN1897959A
(zh)
|
2003-09-29 |
2007-01-17 |
沃伦药品公司 |
用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
|
EP1694706B1
(fr)
|
2003-11-01 |
2012-04-04 |
Merck Patent GmbH |
Anticorps anti-cd52 modifie
|
DK1696947T3
(en)
*
|
2003-12-19 |
2014-03-17 |
Hoffmann La Roche |
APPLICATION OF ERYTHROPOIETIN IN THE TREATMENT OF DISORDERS OF THE IRON DISTRIBUTION IN CHRONIC INFLAMMATORY INTESTINAL DISEASES
|
DK1709161T3
(da)
*
|
2004-01-19 |
2009-01-26 |
Nsgene As |
Humane terapeutiske celler, som udskiller nervevækstfaktor
|
WO2006017621A2
(fr)
|
2004-08-02 |
2006-02-16 |
Janssen Pharmaceutica N.V. |
Variant d'epissage d'irak1c et son utilisation
|
US7893197B2
(en)
|
2004-08-25 |
2011-02-22 |
Janssen Pharmaceutica N.V. |
Relaxin-3 chimeric polypeptides and their preparation and use
|
EP2338993B1
(fr)
|
2004-09-02 |
2013-06-12 |
Yale University |
Régulation d'oncogènes par des micro-ARN
|
CN101389214A
(zh)
|
2004-10-22 |
2009-03-18 |
雷维维科公司 |
具有基因修饰免疫系统的有蹄类动物
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2595676A1
(fr)
*
|
2005-01-25 |
2006-08-03 |
Apollo Life Sciences Limited |
Molecules et leurs molecules chimeriques
|
EP2365086A1
(fr)
|
2005-02-09 |
2011-09-14 |
Bioriginal Food & Science Corporation |
Nouveaux membres de la famille de la désaturase d'acides gras omega-3 et leurs utilisations
|
DK1874282T3
(da)
|
2005-04-06 |
2010-10-25 |
Adamas Pharmaceuticals Inc |
Fremgangsmåder og præparater til behandling af CNS lidelser
|
US8354384B2
(en)
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP2530146A1
(fr)
|
2005-10-13 |
2012-12-05 |
Anthrogenesis Corporation |
Immunomodulation utilisant des cellules souches de placenta
|
US7767420B2
(en)
|
2005-11-03 |
2010-08-03 |
Momenta Pharmaceuticals, Inc. |
Heparan sulfate glycosaminoglycan lyase and uses thereof
|
US8014957B2
(en)
|
2005-12-15 |
2011-09-06 |
Fred Hutchinson Cancer Research Center |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof
|
CN103060263B
(zh)
|
2005-12-29 |
2016-03-16 |
人类起源公司 |
胎盘干细胞群
|
AU2006332679A1
(en)
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Co-culture of placental stem cells and stem cells from a second source
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
SI2004683T1
(sl)
|
2006-03-24 |
2016-09-30 |
Biogen Hemophilia Inc. |
Pc5 kot encim za obdelavo propeptida faktorja ix
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
EP2236623A1
(fr)
|
2006-06-05 |
2010-10-06 |
Cancer Care Ontario |
Evaluation du risque dans le cancer colorectal
|
ES2529234T3
(es)
|
2006-08-04 |
2015-02-18 |
Prolong Pharmaceuticals, LLC |
Eritropoyetina modificada
|
WO2008019062A2
(fr)
*
|
2006-08-04 |
2008-02-14 |
The General Hospital Corporation |
Dérivés polypeptidiques de l'hormone parathyroïdienne (pth)
|
CN101506235B
(zh)
|
2006-09-01 |
2012-07-25 |
人类多细胞株治疗学公司 |
人或人源化免疫球蛋白在非人转基因动物中增强的表达
|
NZ606814A
(en)
|
2006-10-23 |
2014-10-31 |
Anthrogenesis Corp |
Methods and compositions for treatment of bone defects with placental cell populations
|
EP2078075B1
(fr)
*
|
2006-10-30 |
2015-09-02 |
Eli Lilly and Company |
Perturbation génétique homozygote aléatoire pour améliorer la production d'anticorps
|
KR101569168B1
(ko)
|
2007-02-12 |
2015-11-13 |
안트로제네시스 코포레이션 |
태반 줄기세포를 이용한 염증 질환의 치료
|
EP2079839A4
(fr)
|
2007-03-05 |
2009-11-18 |
Cancer Care Ontario |
Évaluation du risque de cancer colorectal
|
EA200971050A1
(ru)
|
2007-05-11 |
2010-06-30 |
Томас Джефферсон Юниверсити |
Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
|
WO2008141176A1
(fr)
|
2007-05-11 |
2008-11-20 |
The Trustees Of The University Of Pennsylvania |
Procédés de traitement des ulcères de la peau
|
US8252897B2
(en)
|
2007-06-21 |
2012-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
AR067537A1
(es)
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Purificacion de polipeptidos pegilados
|
AR067536A1
(es)
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
|
WO2009010107A1
(fr)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
|
CN104072606B
(zh)
|
2007-08-01 |
2017-09-22 |
总医院有限公司 |
利用g蛋白偶联受体和相关组合物的筛选方法
|
US9200253B1
(en)
|
2007-08-06 |
2015-12-01 |
Anthrogenesis Corporation |
Method of producing erythrocytes
|
CA2700643A1
(fr)
|
2007-09-24 |
2009-04-02 |
Cornell University |
Proteines immunogenes provenant d'une membrane exterieure derivee du genome de leptospira et compositions et procedes a base de celles-ci
|
JP5795476B2
(ja)
|
2007-09-28 |
2015-10-14 |
アンスロジェネシス コーポレーション |
ヒト胎盤灌流液およびヒト胎盤由来中間ナチュラルキラー細胞を使用した腫瘍抑制
|
US8501449B2
(en)
|
2007-12-04 |
2013-08-06 |
Proteon Therapeutics, Inc. |
Recombinant elastase proteins and methods of manufacturing and use thereof
|
US20100279423A1
(en)
|
2008-01-02 |
2010-11-04 |
Mark David Brennan |
Genetic markers of mental illness
|
EP2581459A3
(fr)
|
2008-01-17 |
2013-07-17 |
Suregene LLC |
Marqueurs génétiques de maladie mentale
|
JP2011515078A
(ja)
*
|
2008-03-01 |
2011-05-19 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
SPARC特異的miRNAを使用する、治療、診断、及び拮抗物質発見方法
|
WO2009114185A2
(fr)
|
2008-03-12 |
2009-09-17 |
The Rockefeller University |
Procédés et compositions pour profil translationnel et phénotypage moléculaire
|
JP2011519951A
(ja)
*
|
2008-05-07 |
2011-07-14 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
miRNAによる薬物治療の増強
|
DK2330889T3
(en)
|
2008-08-20 |
2017-01-30 |
Anthrogenesis Corp |
Improved cell composition and process for making the same
|
US8962247B2
(en)
|
2008-09-16 |
2015-02-24 |
Sequenom, Inc. |
Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
|
US8476013B2
(en)
|
2008-09-16 |
2013-07-02 |
Sequenom, Inc. |
Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
|
EP2342361A4
(fr)
|
2008-09-25 |
2012-11-14 |
Suregene Llc |
Marqueurs génétiques pour évaluer le risque de développement d'un trouble bipolaire
|
CA2738252C
(fr)
|
2008-09-26 |
2018-05-01 |
Dana-Farber Cancer Institute, Inc. |
Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
|
WO2010037224A1
(fr)
|
2008-10-03 |
2010-04-08 |
St. Michael's Hospital |
Procédé de prévention et de traitement de maladies cardiovasculaires avec brca1
|
US20100120063A1
(en)
*
|
2008-10-10 |
2010-05-13 |
Discoverx Corporation |
GPCR Arrestin Assays
|
EP2348827B1
(fr)
|
2008-10-27 |
2015-07-01 |
Revivicor, Inc. |
Ongulés immunodéprimés
|
ES2723098T3
(es)
|
2008-11-04 |
2019-08-21 |
Janssen Pharmaceutica Nv |
Agonistas del péptido CRHR2 y usos de los mismos
|
WO2010059828A1
(fr)
|
2008-11-19 |
2010-05-27 |
Anthrogenesis Corporation |
Cellules adhérentes issues de l'amnios
|
JP2012515532A
(ja)
|
2009-01-20 |
2012-07-12 |
ラモット アット テル アビブ ユニバーシティ, リミテッド |
Mir−21プロモーター駆動性標的がん治療
|
WO2010088522A2
(fr)
|
2009-01-30 |
2010-08-05 |
Ab Biosciences, Inc. |
Nouveaux anticorps à affinité réduire et applications associées
|
US8211655B2
(en)
*
|
2009-02-12 |
2012-07-03 |
Discoverx Corporation |
Wild-type receptor assays
|
CN102711801A
(zh)
|
2009-11-04 |
2012-10-03 |
詹森药业有限公司 |
用顶压素样肽治疗心力衰竭的方法
|
US8968740B2
(en)
|
2009-11-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
EP3037435B1
(fr)
|
2009-11-17 |
2019-08-07 |
MUSC Foundation for Research Development |
Anticorps monoclonaux humains pour nucléoline humaine
|
ES2577017T3
(es)
|
2009-12-22 |
2016-07-12 |
Sequenom, Inc. |
Procedimientos y kits para identificar la aneuploidia
|
ES2646750T3
(es)
|
2010-01-26 |
2017-12-15 |
Anthrogenesis Corporation |
Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
|
CN102971342B
(zh)
|
2010-01-28 |
2016-08-03 |
Ab生物科学公司 |
亲和力降低的新抗体和制备所述抗体的方法
|
US9631018B2
(en)
|
2010-03-26 |
2017-04-25 |
The Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
NZ630009A
(en)
|
2010-04-07 |
2016-05-27 |
Anthrogenesis Corp |
Angiogenesis using placental stem cells
|
BR112012028949B1
(pt)
|
2010-05-13 |
2020-11-17 |
Chugai Seiyaku Kabushiki Kaisha |
polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica
|
EP2593542B1
(fr)
|
2010-07-13 |
2018-01-03 |
Anthrogenesis Corporation |
Procédés de génération de cellules tueuses naturelles
|
WO2012018387A2
(fr)
|
2010-08-02 |
2012-02-09 |
Population Diagnotics, Inc. |
Compositions et méthodes de recherche de mutations causales dans des troubles génétiques
|
BR112013005890B1
(pt)
|
2010-09-14 |
2022-02-08 |
F Hoffmann-La Roche Ag |
Método para purificar eritropoietina peguilada
|
CA2819635A1
(fr)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Administration dirigee d'agents a une anatomie neuronale
|
EP2471543A1
(fr)
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Induction de tolérance ou immunosuppression pour empêcher en particulier la réaction du greffon contre l'hôte (GvHD) par une pré-incubation de courte durée des suspensions de cellules transplantées, tissus ou organes revêtus par les ligands sur les molécules à la surface des cellules
|
EP2658557A1
(fr)
|
2010-12-31 |
2013-11-06 |
Anthrogenesis Corporation |
Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur
|
AU2012262273B2
(en)
|
2011-06-01 |
2017-09-14 |
Celularity Inc. |
Treatment of pain using placental stem cells
|
WO2013003697A1
(fr)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
|
EP2739734A1
(fr)
|
2011-08-03 |
2014-06-11 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Traitement de fibrose au moyen de microarn-19b
|
CA2851388C
(fr)
|
2011-10-10 |
2023-11-21 |
The Hospital For Sick Children |
Methodes et compositions de depistage et de traitement de troubles du developpement
|
DK2773779T3
(da)
|
2011-11-04 |
2020-11-23 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
|
WO2013120018A1
(fr)
|
2012-02-09 |
2013-08-15 |
Population Diagnostics, Inc. |
Méthodes et compositions permettant de rechercher et de traiter des troubles du développement
|
PL2814842T3
(pl)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk A/S |
Przeciwciała wiążące białko 1 rozpoznające peptydoglikan
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
ES2640268T3
(es)
|
2012-02-15 |
2017-11-02 |
Novo Nordisk A/S |
Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
|
ES2930180T3
(es)
|
2012-03-02 |
2022-12-07 |
Sequenom Inc |
Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
|
US9494597B2
(en)
|
2012-04-02 |
2016-11-15 |
Ab Biosciences, Inc. |
Human control antibodies and uses therefor
|
US20130280222A1
(en)
*
|
2012-04-18 |
2013-10-24 |
Board Of Regents Of The University Of Texas System |
Non-disruptive gene targeting
|
US9920361B2
(en)
|
2012-05-21 |
2018-03-20 |
Sequenom, Inc. |
Methods and compositions for analyzing nucleic acid
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014011928A1
(fr)
|
2012-07-13 |
2014-01-16 |
Sequenom, Inc. |
Procédés et compositions pour l'enrichissement basé sur la méthylation d'un échantillon maternel en acide nucléique fœtal, utiles pour les diagnostics prénatals non invasifs
|
CA2884704C
(fr)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Modulateurs vista de diagnostic et de traitement de cancer
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
CA2922005A1
(fr)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Procedes et compositions de depistage et de traitement de troubles du developpement
|
CN103864913A
(zh)
|
2012-12-18 |
2014-06-18 |
联亚生技开发股份有限公司 |
重组蛋白
|
CN115137753A
(zh)
|
2013-02-05 |
2022-10-04 |
细胞结构公司 |
来自胎盘的自然杀伤细胞
|
WO2014168711A1
(fr)
|
2013-03-13 |
2014-10-16 |
Sequenom, Inc. |
Amorces pour analyse de la méthylation de l'adn
|
EP2968450A4
(fr)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
Toxines modifiées
|
WO2014138921A1
(fr)
|
2013-03-15 |
2014-09-18 |
Apotex Inc. |
Stabilité de la formulation liquide améliorée d'érythropoïétine alpha par l'intermédiaire d'un traitement de purification
|
US10294295B2
(en)
|
2013-11-27 |
2019-05-21 |
Inis Biotech Llc |
Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015097536A2
(fr)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anticorps et fragments anti-vista
|
EP3736344A1
(fr)
|
2014-03-13 |
2020-11-11 |
Sequenom, Inc. |
Méthodes et procédés d'évaluation non invasive de variations génétiques
|
JP2017509328A
(ja)
|
2014-03-21 |
2017-04-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ヌクレアーゼを使用しないゲノム編集
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
WO2016036403A1
(fr)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Méthodes et compositions destinées à inhiber et à traiter des états neurologiques
|
EP3194581A4
(fr)
|
2014-09-15 |
2018-04-25 |
Children's Medical Center Corporation |
Méthodes et compositions pour augmenter l'efficacité du transfert nucléaire des cellules somatiques (scnt) par élimination de la triméthylation de la lysine de l'histone h3
|
EP3015475A1
(fr)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Cellules de mammifère exprimant des antigènes du cytomégalovirus
|
WO2016090347A1
(fr)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification de vsig8 en tant que récepteur putatif de vista et son utilisation pour produire des modulateurs de vista/vsig8
|
EP3031822A1
(fr)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Antigènes du cytomégalovirus
|
EP3048114A1
(fr)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Antigènes du cytomégalovirus et leurs utilisations
|
US10632151B2
(en)
|
2015-01-22 |
2020-04-28 |
University Of Massachusetts |
Cancer immunotherapy
|
EP3047856A1
(fr)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Antigènes de cytomégalovirus (cmv) et leurs utilisations
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
CN109789201B
(zh)
|
2016-04-15 |
2023-06-16 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
JP7177035B2
(ja)
|
2016-07-15 |
2022-11-22 |
エフ.ホフマン-ラ ロシュ アーゲー |
Peg化エリスロポエチンを精製するための方法
|
WO2018144807A2
(fr)
*
|
2017-02-02 |
2018-08-09 |
Massachusetts Institute Of Technology |
Levure modifiée en tant que procédé de bioremédiation
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
CN111801120A
(zh)
|
2017-12-29 |
2020-10-20 |
豪夫迈·罗氏有限公司 |
用于提供聚乙二醇化蛋白质组合物的方法
|
US20200323993A1
(en)
|
2017-12-29 |
2020-10-15 |
Hoffmann-La Roche Inc. |
Process for providing pegylated protein composition
|
EP3731873B1
(fr)
|
2017-12-29 |
2022-01-26 |
F. Hoffmann-La Roche AG |
Procédé de fournir des protéines monopégylée
|
SI3625368T1
(sl)
|
2018-08-08 |
2023-04-28 |
Pml Screening, Llc |
Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
|
EP4004018A1
(fr)
|
2019-07-24 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Protéines de cytomégalovirus humain modifiées
|
WO2022159414A1
(fr)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Érythropoïétine pour un dysfonctionnement gastrointestinal
|
WO2023144665A1
(fr)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Protéines de cytomégalovirus humain modifiées
|
WO2024091824A1
(fr)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Différenciation et reprogrammation de chondrocyte
|
WO2024129459A1
(fr)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Réparation d'un dysfonctionnement de la barrière dans l'œsophage
|